• Many asthma patients across the EU5 (France, Germany, Italy, Spain, the United Kingdom) require lifelong treatment to manage their condition. This places a substantial financial burden on the national healthcare systems, and the launch of novel, premium-priced biologic therapies targeted at severe refractory asthma will undoubtedly exert additional pressure.
• The behavior of payers—as they strive to control disease-associated costs—will play an increasingly influential role in shaping the market access landscape for asthma in the EU5, such that emerging biologics must compete to prove their worth.
• Against a backdrop of budget constraints and increasing competition, this research explored the evolving reimbursement and prescribing environment for asthma biologics seeking to secure optimal market access.

Authors: Elena Kozhemyakina, Ph.D.; Andrea Kravit ; Janie Cox, Ph.D.

How Glympse Bio oversubscribed their Series B funding amidst the pandemic

View Now